Muscular pseudohypertrophy-hypothyroidism syndrome

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:2349E03.1
Who is this for?
Show terms as
1Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Muscular pseudohypertrophy-hypothyroidism syndrome, also known as Kocher-Debré-Sémélaigne syndrome, is a rare condition characterized by the combination of congenital or acquired hypothyroidism with generalized muscular pseudohypertrophy (enlarged muscles that appear well-developed but are actually weak). This syndrome predominantly affects children and is caused by longstanding, untreated or inadequately treated hypothyroidism. The muscular enlargement gives the child a 'Herculean' or athletic appearance despite significant muscle weakness and stiffness. The condition primarily affects the skeletal muscular system and the endocrine system. Key clinical features include diffuse enlargement of muscles (particularly in the calves, thighs, and arms), muscle stiffness, slowness of movement, muscle weakness, and the classic signs of hypothyroidism such as growth retardation, delayed bone age, fatigue, constipation, dry skin, and intellectual slowing. The muscles may feel firm and rubbery on palpation. Laboratory findings typically reveal elevated thyroid-stimulating hormone (TSH), low thyroid hormone levels (T3 and T4), and often markedly elevated creatine kinase levels reflecting muscle involvement. The condition is generally reversible with appropriate thyroid hormone replacement therapy. Treatment with levothyroxine leads to gradual resolution of the muscular pseudohypertrophy and improvement in muscle strength, along with correction of the hypothyroid state. Early diagnosis and treatment are important to prevent long-term complications including growth failure and neurodevelopmental delay. The prognosis is excellent when thyroid replacement therapy is initiated promptly.

Also known as:

Clinical phenotype terms— hover any for plain English:

Age of Onset

Childhood

Begins in childhood, roughly ages 1 to 12

Orphanet ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Muscular pseudohypertrophy-hypothyroidism syndrome.

View clinical trials →

No actively recruiting trials found for Muscular pseudohypertrophy-hypothyroidism syndrome at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Muscular pseudohypertrophy-hypothyroidism syndrome community →

Specialists

1 foundView all specialists →

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Muscular pseudohypertrophy-hypothyroidism syndrome.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Muscular pseudohypertrophy-hypothyroidism syndromeForum →

No community posts yet. Be the first to share your experience with Muscular pseudohypertrophy-hypothyroidism syndrome.

Start the conversation →

Latest news about Muscular pseudohypertrophy-hypothyroidism syndrome

No recent news articles for Muscular pseudohypertrophy-hypothyroidism syndrome.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Muscular pseudohypertrophy-hypothyroidism syndrome

What is Muscular pseudohypertrophy-hypothyroidism syndrome?

Muscular pseudohypertrophy-hypothyroidism syndrome, also known as Kocher-Debré-Sémélaigne syndrome, is a rare condition characterized by the combination of congenital or acquired hypothyroidism with generalized muscular pseudohypertrophy (enlarged muscles that appear well-developed but are actually weak). This syndrome predominantly affects children and is caused by longstanding, untreated or inadequately treated hypothyroidism. The muscular enlargement gives the child a 'Herculean' or athletic appearance despite significant muscle weakness and stiffness. The condition primarily affects the sk

At what age does Muscular pseudohypertrophy-hypothyroidism syndrome typically begin?

Typical onset of Muscular pseudohypertrophy-hypothyroidism syndrome is childhood. Age of onset can vary across affected individuals.

Which specialists treat Muscular pseudohypertrophy-hypothyroidism syndrome?

1 specialists and care centers treating Muscular pseudohypertrophy-hypothyroidism syndrome are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.